---
layout: post
title: "Proposal To Refuse To Approve a New Drug Application for Sotagliflozin Oral Tablets, 200 Milligrams and 400 Milligrams; Opportunity for a Hearing"
date: 2026-02-05 19:08:40 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-04342
original_published: 2021-03-03 00:00:00 +0000
significance: 8.00
---

# Proposal To Refuse To Approve a New Drug Application for Sotagliflozin Oral Tablets, 200 Milligrams and 400 Milligrams; Opportunity for a Hearing

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 03, 2021 00:00 UTC
**Document Number:** 2021-04342

## Summary

The Director of the Center for Drug Evaluation and Research (Center Director) of the Food and Drug Administration (FDA or Agency) is proposing to refuse to approve a new drug application (NDA) submitted by Lexicon Pharmaceuticals, Inc. (Lexicon) for sotagliflozin oral tablets, 200 milligrams (mg) and 400 mg, in its present form. This notice summarizes the grounds for the Center Director's proposal and offers Lexicon an opportunity to request a hearing on the matter.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/03/03/2021-04342/proposal-to-refuse-to-approve-a-new-drug-application-for-sotagliflozin-oral-tablets-200-milligrams)
- API: https://www.federalregister.gov/api/v1/documents/2021-04342

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
